MoonLake Reports Strong Phase 3 Results for Sonelokimab Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: stocktwits
- Clinical Trial Success: MoonLake's Sonelokimab demonstrated impressive results in Phase 3 trials, with 67.2% of patients showing significant improvement after one year, and 33.1% achieving complete skin clearance, outperforming a competing IL-17 inhibitor by over 10 percentage points, highlighting its potential in treating chronic skin conditions.
- Adolescent Patient Response: In the Vela-Teen study, nearly 68% of adolescent patients achieved a strong treatment response within 24 weeks, with about 45% achieving complete skin clearance, and no new safety concerns identified, laying the groundwork for broader market expansion for Sonelokimab.
- FDA Application Plans: MoonLake is on track to submit a Biologics License Application (BLA) to the FDA by the end of September, requesting Priority Review which could shorten the review process by about three months, potentially leading to a market launch in the second half of 2027, further boosting investor confidence.
- Investor Day Insights: The company will discuss commercialization plans and regulatory strategies at its Investor Day on June 22, with investors eagerly anticipating upcoming late-stage data from its psoriatic arthritis pipeline, reflecting strong market interest in Sonelokimab.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 19.190
Low
5.00
Averages
24.10
High
45.00
Current: 19.190
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MoonLake Reports Phase 3 VELA Trial Results for HS Treatment
- Clinical Trial Success: In the Week 52 results of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% reached HiSCR100, demonstrating sonelokimab's superior efficacy in treating moderate-to-severe HS, potentially positioning it as a best-in-class therapy.
- Quality of Life Improvement: Patients reported a mean HiSQOL score improvement of 15.0 points at Week 52, indicating significant enhancements in their quality of life, reflecting sonelokimab's potential in alleviating symptoms and improving daily living for HS patients.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming sonelokimab's favorable safety profile over long-term use, thereby enhancing its credibility as a candidate for HS treatment.
- Future Plans: MoonLake intends to submit a Biologics License Application (BLA) by the end of September 2026 and will host an Investor Day webcast on June 22, 2026, to discuss clinical data and future developments, showcasing the company's commitment to HS treatment.
See More
MoonLake Immunotherapeutics Reports Strong VELA Trial Results for Sonelokimab
- Clinical Trial Results: At Week 52 of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100 with sonelokimab, demonstrating its superior efficacy in treating moderate-to-severe hidradenitis suppurativa compared to competitors.
- Quality of Life Improvement: Patients reported a mean improvement of 15.0 points in HS-specific quality of life scores (HiSQOL) at Week 52, indicating a shift from 'severe' to 'mild' impairment, which not only enhances patient satisfaction but also strengthens the company's competitive position in the market.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming the long-term safety of sonelokimab, which supports its future marketability and acceptance among healthcare providers.
- Future Plans: MoonLake plans to submit a Biologics License Application (BLA) by the end of September 2026 and will hold an Investor Day webcast on June 22, 2026, to discuss these findings and outline its commercialization strategy.
See More
US-Iran Negotiations and Market Reactions
- US-Iran Negotiation Progress: US Vice President J.D. Vance met with Iranian officials in Switzerland to discuss strategies for maintaining the ceasefire, amidst a backdrop where 65% of Americans disapprove of President Trump's handling of Iran, potentially impacting future negotiations.
- Market Sentiment Volatility: Market sentiment weakened as Iran restricted traffic through the Strait of Hormuz, leading to a 0.12% drop in Dow futures, a 0.21% decline in S&P 500 futures, and a 0.22% decrease in Nasdaq 100 futures, reflecting investor concerns over the situation.
- Oil Price Increase: Amid escalating tensions, Brent crude futures rose to around $80.25 per barrel, while WTI crude futures climbed 1.20% to approximately $77.52 per barrel, indicating market worries about potential supply disruptions.
- Economic Data Focus: Markets will closely watch May's core Personal Consumption Expenditures data, the Fed's preferred inflation gauge, especially after the Fed kept interest rates unchanged, with expectations of a rate hike in 2026 that could influence future market trends.
See More
MoonLake Reports Strong Phase 3 Results for Sonelokimab Treatment
- Clinical Trial Success: MoonLake's Sonelokimab demonstrated impressive results in Phase 3 trials, with 67.2% of patients showing significant improvement after one year, and 33.1% achieving complete skin clearance, outperforming a competing IL-17 inhibitor by over 10 percentage points, highlighting its potential in treating chronic skin conditions.
- Adolescent Patient Response: In the Vela-Teen study, nearly 68% of adolescent patients achieved a strong treatment response within 24 weeks, with about 45% achieving complete skin clearance, and no new safety concerns identified, laying the groundwork for broader market expansion for Sonelokimab.
- FDA Application Plans: MoonLake is on track to submit a Biologics License Application (BLA) to the FDA by the end of September, requesting Priority Review which could shorten the review process by about three months, potentially leading to a market launch in the second half of 2027, further boosting investor confidence.
- Investor Day Insights: The company will discuss commercialization plans and regulatory strategies at its Investor Day on June 22, with investors eagerly anticipating upcoming late-stage data from its psoriatic arthritis pipeline, reflecting strong market interest in Sonelokimab.
See More
MoonLake's Sonelokimab Shows Promising Phase 3 Results for Hidradenitis Suppurativa
- Clinical Trial Success: MoonLake's experimental drug sonelokimab demonstrated that 67.2% of patients achieved at least a 75% reduction in inflammatory lesions after 52 weeks in two Phase 3 trials, indicating significant efficacy in treating hidradenitis suppurativa and positioning it as a strong market competitor.
- Regulatory Submission Plans: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by the end of September, with potential market entry by late 2027 or earlier if granted Priority Review, highlighting its commercial potential.
- Adolescent Patient Data: In the VELA-TEEN study involving adolescent patients, nearly 68% achieved HiSCR75 and approximately 45% reached HiSCR100 at 24 weeks, suggesting the drug's effectiveness in younger populations and potential market expansion.
- Improved Quality of Life: Patient-reported outcomes indicated substantial improvements in quality of life, with nearly half of participants experiencing at least a three-point improvement on a standardized pain scale, demonstrating that sonelokimab positively impacts both clinical and subjective patient experiences.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
MoonLake Reports Phase 3 VELA Trial Results for HS Treatment
- Clinical Trial Success: In the Week 52 results of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% reached HiSCR100, demonstrating sonelokimab's superior efficacy in treating moderate-to-severe HS, potentially positioning it as a best-in-class therapy.
- Quality of Life Improvement: Patients reported a mean HiSQOL score improvement of 15.0 points at Week 52, indicating significant enhancements in their quality of life, reflecting sonelokimab's potential in alleviating symptoms and improving daily living for HS patients.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming sonelokimab's favorable safety profile over long-term use, thereby enhancing its credibility as a candidate for HS treatment.
- Future Plans: MoonLake intends to submit a Biologics License Application (BLA) by the end of September 2026 and will host an Investor Day webcast on June 22, 2026, to discuss clinical data and future developments, showcasing the company's commitment to HS treatment.
See More
MoonLake Immunotherapeutics Reports Strong VELA Trial Results for Sonelokimab
- Clinical Trial Results: At Week 52 of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100 with sonelokimab, demonstrating its superior efficacy in treating moderate-to-severe hidradenitis suppurativa compared to competitors.
- Quality of Life Improvement: Patients reported a mean improvement of 15.0 points in HS-specific quality of life scores (HiSQOL) at Week 52, indicating a shift from 'severe' to 'mild' impairment, which not only enhances patient satisfaction but also strengthens the company's competitive position in the market.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming the long-term safety of sonelokimab, which supports its future marketability and acceptance among healthcare providers.
- Future Plans: MoonLake plans to submit a Biologics License Application (BLA) by the end of September 2026 and will hold an Investor Day webcast on June 22, 2026, to discuss these findings and outline its commercialization strategy.
See More
US-Iran Negotiations and Market Reactions
- US-Iran Negotiation Progress: US Vice President J.D. Vance met with Iranian officials in Switzerland to discuss strategies for maintaining the ceasefire, amidst a backdrop where 65% of Americans disapprove of President Trump's handling of Iran, potentially impacting future negotiations.
- Market Sentiment Volatility: Market sentiment weakened as Iran restricted traffic through the Strait of Hormuz, leading to a 0.12% drop in Dow futures, a 0.21% decline in S&P 500 futures, and a 0.22% decrease in Nasdaq 100 futures, reflecting investor concerns over the situation.
- Oil Price Increase: Amid escalating tensions, Brent crude futures rose to around $80.25 per barrel, while WTI crude futures climbed 1.20% to approximately $77.52 per barrel, indicating market worries about potential supply disruptions.
- Economic Data Focus: Markets will closely watch May's core Personal Consumption Expenditures data, the Fed's preferred inflation gauge, especially after the Fed kept interest rates unchanged, with expectations of a rate hike in 2026 that could influence future market trends.
See More
MoonLake Reports Strong Phase 3 Results for Sonelokimab Treatment
- Clinical Trial Success: MoonLake's Sonelokimab demonstrated impressive results in Phase 3 trials, with 67.2% of patients showing significant improvement after one year, and 33.1% achieving complete skin clearance, outperforming a competing IL-17 inhibitor by over 10 percentage points, highlighting its potential in treating chronic skin conditions.
- Adolescent Patient Response: In the Vela-Teen study, nearly 68% of adolescent patients achieved a strong treatment response within 24 weeks, with about 45% achieving complete skin clearance, and no new safety concerns identified, laying the groundwork for broader market expansion for Sonelokimab.
- FDA Application Plans: MoonLake is on track to submit a Biologics License Application (BLA) to the FDA by the end of September, requesting Priority Review which could shorten the review process by about three months, potentially leading to a market launch in the second half of 2027, further boosting investor confidence.
- Investor Day Insights: The company will discuss commercialization plans and regulatory strategies at its Investor Day on June 22, with investors eagerly anticipating upcoming late-stage data from its psoriatic arthritis pipeline, reflecting strong market interest in Sonelokimab.
See More
MoonLake's Sonelokimab Shows Promising Phase 3 Results for Hidradenitis Suppurativa
- Clinical Trial Success: MoonLake's experimental drug sonelokimab demonstrated that 67.2% of patients achieved at least a 75% reduction in inflammatory lesions after 52 weeks in two Phase 3 trials, indicating significant efficacy in treating hidradenitis suppurativa and positioning it as a strong market competitor.
- Regulatory Submission Plans: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by the end of September, with potential market entry by late 2027 or earlier if granted Priority Review, highlighting its commercial potential.
- Adolescent Patient Data: In the VELA-TEEN study involving adolescent patients, nearly 68% achieved HiSCR75 and approximately 45% reached HiSCR100 at 24 weeks, suggesting the drug's effectiveness in younger populations and potential market expansion.
- Improved Quality of Life: Patient-reported outcomes indicated substantial improvements in quality of life, with nearly half of participants experiencing at least a three-point improvement on a standardized pain scale, demonstrating that sonelokimab positively impacts both clinical and subjective patient experiences.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
